TR200502522T2 - Çözünmez bir aktif madde içeren farmasötik formülasyon - Google Patents
Çözünmez bir aktif madde içeren farmasötik formülasyonInfo
- Publication number
- TR200502522T2 TR200502522T2 TR2005/02522T TR200502522T TR200502522T2 TR 200502522 T2 TR200502522 T2 TR 200502522T2 TR 2005/02522 T TR2005/02522 T TR 2005/02522T TR 200502522 T TR200502522 T TR 200502522T TR 200502522 T2 TR200502522 T2 TR 200502522T2
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutical formulation
- active ingredient
- formulation containing
- particles
- insoluble active
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 3
- 210000004072 lung Anatomy 0.000 abstract 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43721002P | 2002-12-31 | 2002-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200502522T2 true TR200502522T2 (tr) | 2005-09-21 |
Family
ID=32713146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2005/02522T TR200502522T2 (tr) | 2002-12-31 | 2003-12-31 | Çözünmez bir aktif madde içeren farmasötik formülasyon |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040156792A1 (https=) |
| EP (1) | EP1589947B2 (https=) |
| JP (1) | JP2006513236A (https=) |
| KR (1) | KR20050095838A (https=) |
| CN (1) | CN1741789A (https=) |
| AU (1) | AU2003300137A1 (https=) |
| BR (1) | BR0317810A (https=) |
| CA (1) | CA2511523C (https=) |
| EA (1) | EA200501001A1 (https=) |
| ES (1) | ES2589578T5 (https=) |
| HU (1) | HUP0500846A3 (https=) |
| MX (1) | MXPA05007158A (https=) |
| NO (1) | NO20053076L (https=) |
| PL (1) | PL378270A1 (https=) |
| PT (1) | PT1589947T (https=) |
| TR (1) | TR200502522T2 (https=) |
| WO (1) | WO2004060351A2 (https=) |
| ZA (1) | ZA200505155B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| JP2006513235A (ja) * | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 真菌感染症療法のためのエアゾール化可能な医薬製剤 |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| US8513204B2 (en) * | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| WO2006026502A1 (en) * | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| CA2623256A1 (en) * | 2005-09-29 | 2007-04-12 | Nektar Therapeutics | Receptacles and kits, such as for dry powder packaging |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| US20120128728A1 (en) * | 2005-12-28 | 2012-05-24 | Novartis Pharma Ag | Compositions Comprising Amphotericin B |
| IN2015DN00888A (https=) * | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| DE102006053375A1 (de) * | 2006-11-10 | 2008-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Mischung von Pulvern |
| SI2170279T1 (en) * | 2007-07-31 | 2018-04-30 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
| EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| PL220269B1 (pl) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego |
| MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
| EP3552602B1 (en) | 2009-03-18 | 2025-03-05 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| EP2411137B1 (en) | 2009-03-27 | 2016-09-07 | Bend Research, Inc. | Spray-drying process |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| WO2012031133A2 (en) | 2010-09-03 | 2012-03-08 | Bench Research, Inc. | Spray-drying apparatus and methods of using the same |
| WO2012040502A1 (en) | 2010-09-24 | 2012-03-29 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| AU2011320159B2 (en) | 2010-10-29 | 2016-12-22 | Western University Of Health Sciences | Ternary mixture formulations |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| CN106061487A (zh) * | 2014-02-03 | 2016-10-26 | 里兰斯坦福初级大学理事会 | 用于微粒递送锌原卟啉的制剂 |
| WO2016067132A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
| CN104587457B (zh) * | 2015-01-13 | 2017-03-22 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
| CA3008996A1 (en) * | 2015-12-24 | 2017-06-29 | Philip Morris Products S.A. | Nicotine particle capsule |
| CN109069495A (zh) | 2016-02-01 | 2018-12-21 | 英凯达治疗公司 | 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常 |
| AU2018266199A1 (en) | 2017-05-10 | 2019-11-07 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| IL269275B2 (en) * | 2017-06-28 | 2023-04-01 | Philip Morris Products Sa | Container with particles for use with an inhaler |
| US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
| GB201817860D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolised formulation |
| GB201817863D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| GB201817865D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| AU2020323594B2 (en) | 2019-08-01 | 2022-02-03 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US437210A (en) | 1890-09-30 | Electric street-car | ||
| SE408265B (sv) * | 1975-12-12 | 1979-06-05 | Draco Ab | Anordning for koldioxiddriven endosaerosol, avsedd for inhalering |
| US4247066A (en) * | 1978-02-21 | 1981-01-27 | General Dynamics Corporation | Airfoil variable cambering device and method |
| IT1116047B (it) * | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
| DE3634952A1 (de) * | 1986-10-14 | 1988-04-21 | Bayer Ag | Imidazo-pyrrolo-pyridin-derivate |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| DE69230613T2 (de) * | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
| US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| JP3388896B2 (ja) * | 1994-08-08 | 2003-03-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| ATE287703T1 (de) * | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| AU5719798A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| AU756693B2 (en) * | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6257233B1 (en) * | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| WO2000001365A1 (en) † | 1998-06-30 | 2000-01-13 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Prolonged release ophthalmic compositions containing a fluoroquinolone |
| US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| PT1280520E (pt) † | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US6357490B1 (en) * | 2000-08-22 | 2002-03-19 | Advanced Inhalation Research, Inc. | System, method and apparatus for filling containers |
| KR100743404B1 (ko) * | 2000-12-21 | 2007-07-30 | 넥타르 테라퓨틱스 | 폴리엔 항균제의 폐 전달 |
-
2003
- 2003-12-31 US US10/750,934 patent/US20040156792A1/en not_active Abandoned
- 2003-12-31 JP JP2004564917A patent/JP2006513236A/ja not_active Withdrawn
- 2003-12-31 ES ES03800395T patent/ES2589578T5/es not_active Expired - Lifetime
- 2003-12-31 WO PCT/US2003/041703 patent/WO2004060351A2/en not_active Ceased
- 2003-12-31 EP EP03800395.0A patent/EP1589947B2/en not_active Expired - Lifetime
- 2003-12-31 CA CA2511523A patent/CA2511523C/en not_active Expired - Fee Related
- 2003-12-31 TR TR2005/02522T patent/TR200502522T2/xx unknown
- 2003-12-31 KR KR1020057012444A patent/KR20050095838A/ko not_active Withdrawn
- 2003-12-31 PT PT38003950T patent/PT1589947T/pt unknown
- 2003-12-31 MX MXPA05007158A patent/MXPA05007158A/es unknown
- 2003-12-31 HU HU0500846A patent/HUP0500846A3/hu unknown
- 2003-12-31 PL PL378270A patent/PL378270A1/pl unknown
- 2003-12-31 EA EA200501001A patent/EA200501001A1/ru unknown
- 2003-12-31 CN CNA2003801091328A patent/CN1741789A/zh active Pending
- 2003-12-31 BR BR0317810-2A patent/BR0317810A/pt not_active IP Right Cessation
- 2003-12-31 AU AU2003300137A patent/AU2003300137A1/en not_active Abandoned
-
2005
- 2005-06-23 NO NO20053076A patent/NO20053076L/no not_active Application Discontinuation
- 2005-06-24 ZA ZA200505155A patent/ZA200505155B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004060351A2 (en) | 2004-07-22 |
| BR0317810A (pt) | 2005-11-29 |
| CN1741789A (zh) | 2006-03-01 |
| US20040156792A1 (en) | 2004-08-12 |
| EP1589947B2 (en) | 2019-01-30 |
| JP2006513236A (ja) | 2006-04-20 |
| CA2511523A1 (en) | 2004-07-22 |
| EP1589947B8 (en) | 2016-08-24 |
| ES2589578T5 (es) | 2019-07-23 |
| PT1589947T (pt) | 2016-09-05 |
| MXPA05007158A (es) | 2005-09-21 |
| ES2589578T3 (es) | 2016-11-15 |
| NO20053076D0 (no) | 2005-06-23 |
| WO2004060351A3 (en) | 2004-09-30 |
| EA200501001A1 (ru) | 2005-12-29 |
| EP1589947B1 (en) | 2016-06-15 |
| EP1589947A2 (en) | 2005-11-02 |
| ZA200505155B (en) | 2006-04-26 |
| KR20050095838A (ko) | 2005-10-04 |
| NO20053076L (no) | 2005-09-13 |
| HUP0500846A2 (en) | 2008-05-28 |
| CA2511523C (en) | 2013-10-15 |
| HUP0500846A3 (en) | 2008-10-28 |
| PL378270A1 (pl) | 2006-03-20 |
| AU2003300137A1 (en) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200502522T2 (tr) | Çözünmez bir aktif madde içeren farmasötik formülasyon | |
| Ahmad et al. | Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses | |
| JP5577021B2 (ja) | 動物における障害を治療および予防するための薬剤組成物の経粘膜投与 | |
| ES2192866T3 (es) | Polvo seco para inhalacion. | |
| US7060730B2 (en) | Rapidly absorbed liquid compositions | |
| ES2054174T3 (es) | Preparado farmaceutico de particulas para via oral que se liberan rapidamente con un sabor desagradable enmascarado. | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| CO5271759A1 (es) | Formulacion en solucion que contiene una mezcla de disolventes | |
| JO2381B1 (en) | Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease | |
| KR20040063909A (ko) | 구강, 비강 또는 질강에 항박테리아성, 항진균성, 및항바이러스성 연고를 전달하는 조성물과 방법 | |
| CY1107315T1 (el) | Φαρμακευτικα σκευασματα για εισπνεομενα ξηρας σκονης υπο μορφη σκληρων σβωλων | |
| UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
| AR022090A1 (es) | PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN | |
| AR030253A1 (es) | Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento | |
| US5126348A (en) | Bioavailability enhancers | |
| JO3102B1 (ar) | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة | |
| ATE529097T1 (de) | Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff | |
| AR030862A1 (es) | Formulaciones medicinales en aerosol | |
| SG146638A1 (en) | Pharmaceutical delivery system | |
| PL295329A1 (en) | Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside | |
| AR032614A1 (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
| GR20030100286A (el) | Μορφηαφαρμακευτικησαδοσολογιασαπουαφερειαφιλικεσαπροσατηνακυησηαενδειξεις | |
| JPH1045576A (ja) | 鼻炎用内服薬 | |
| CA2653017A1 (en) | Robust sustained release formulations of oxymorphone and methods of use thereof | |
| JP2001288117A5 (https=) |